These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21552020)

  • 21. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
    Börner AR; Müller-Gärtner HW
    Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iodine-131 contamination from thyroid cancer patients.
    Ibis E; Wilson CR; Collier BD; Akansel G; Isitman AT; Yoss RG
    J Nucl Med; 1992 Dec; 33(12):2110-5. PubMed ID: 1460501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
    Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
    Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioiodine and radiotherapy in the management of thyroid cancers.
    Simpson WJ
    Otolaryngol Clin North Am; 1990 Jun; 23(3):509-21. PubMed ID: 1694984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient
    Gomes-Lima CJ; Wu D; Kharazi PH; Khojekar GJ; Ringel MD; Vetter RJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2017 Dec; 27(12):1558-1565. PubMed ID: 29132255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
    Lassmann M; Luster M; Hänscheid H; Reiners C
    J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
    [No Abstract]   [Full Text] [Related]  

  • 30. Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
    Culver CM; Dworkin HJ
    J Nucl Med; 1992 Jul; 33(7):1402-5. PubMed ID: 1613585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of radioiodine in management of thyroid cancer: experience with 70 cases.
    Afroz S; Ahmed K; Yasmeen S; Ahmed F; Nisa L
    Bangladesh Med Res Counc Bull; 1992 Dec; 18(2):68-71. PubMed ID: 1303083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine therapy during an unknown remained pregnancy and radiation exposure of the fetus. A case report.
    Arndt D; Mehnert WH; Franke WG; Woller P; Laude G; Rockel A; Waller M
    Strahlenther Onkol; 1994 Jul; 170(7):408-14. PubMed ID: 8052940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
    Clarke SE
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
    Günter HH; Junker D; Schober O; Hundeshagen H
    Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
    Katz N; Esik O; Füzy M; Gundy S
    Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hand exposure of nuclear medicine workers during administration of radioiodine.
    Wrzesien M; Olszewski J
    Radiat Prot Dosimetry; 2012 Aug; 151(1):147-52. PubMed ID: 22147924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outpatient therapeutic nuclear oncology.
    Turner JH
    Ann Nucl Med; 2012 May; 26(4):289-97. PubMed ID: 22222779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation doses to patient's relatives following radioiodine therapy.
    Sulaiman BT; Clarke SE
    Med J Malaysia; 1996 Mar; 51(1):131-3. PubMed ID: 10967992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial dose mapping for individualizing radioiodine treatment.
    Lassmann M; Hänscheid H
    J Nucl Med; 2007 Jan; 48(1):2-4. PubMed ID: 17204691
    [No Abstract]   [Full Text] [Related]  

  • 40. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.